Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has appointed Raymond F. Vennare as its new chief executive officer, effective Nov. 1, 2022; Vennare will also assume the role of board chair. Vennare has more than 30 years’ experience building and leading biotechnology and bioinformatics companies across diverse markets in life sciences and has been an active member on the POAI board of directors since September 2021. According to the announcement, Vennare will work closely with the company’s senior leadership team to expand its portfolio of proprietary solutions and advance the pipeline of drug development in oncology. He will also oversee POAI’s work on evolving the company’s core products and services. Vennare has a long career focused on founding, advising and leading companies in both the private and public sectors; his companies have operated in the bioinformatics, diagnostics and therapeutic drug delivery spaces, and he has played a key role in company formation, capitalization, business development and execution of commercialization opportunities for novel technologies. “We are fortunate to have Raymond leading Predictive Oncology at this pivotal time in our company’s evolution,” said Predictive Oncology chief financial officer Bob Myers in the press release. “He is an experienced biotechnology executive who brings an informed vision and fresh perspective to our company as we strive to become a significant player in the pharmaceutical and biotech industries. He has the right balance of entrepreneurship, innovation, technology commercialization and strategic thinking that makes him the right fit to grow our business.”
To view the full press release, visit https://ibn.fm/EtE6K
About Predictive Oncology Inc.
Predictive Oncology is a knowledge-driven company focused on applying artificial intelligence (AI) to develop optimal cancer therapies, which can lead to more effective treatments and improved patient outcomes. Through AI, Predictive Oncology uses a biobank of 150,000+ cancer tumors, categorized by patient type, against drug compounds to help the drug discovery process and increase the probability of success. The company offers a suite of solutions for oncology drug development from early discovery to clinical trials. For more information about the company, please visit www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.